Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay

PURPOSE: The GenesWell™ breast cancer test (BCT) is a recently developed multigene assay that predicts the risk of distant recurrence in patients with hormone receptor-positive (HR+) and human epidermal growth factor-2 negative (HER2−) early breast cancer (BC). The ability of this assay to predict t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jun-Hee, Ryu, Jai Min, Ahn, Jee Hyun, Cho, Soo Youn, Lee, Se Kyung, Yu, Jonghan, Chae, Byung Joo, Nam, Seok Jin, Han, Jinil, Lee, Jeong Eon, Kim, Seok Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807325/
https://www.ncbi.nlm.nih.gov/pubmed/36479604
http://dx.doi.org/10.4048/jbc.2022.25.e49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807325/
https://www.ncbi.nlm.nih.gov/pubmed/36479604
http://dx.doi.org/10.4048/jbc.2022.25.e49

Ejemplares similares